Jhon Soto - Academia.edu (original) (raw)
Papers by Jhon Soto
Supplemental Methods; Supplemental Figure legends; Supplemental Table 1; Figure S1, S2, S3, S4, S... more Supplemental Methods; Supplemental Figure legends; Supplemental Table 1; Figure S1, S2, S3, S4, S5, S6, S7, S8 and S9
The principle of intangible value in the world has acquired relevance as a corporate and social s... more The principle of intangible value in the world has acquired relevance as a corporate and social strategy, while in Peru it has been disseminated only at the academic level and its implementation in the various sectors has been very poor. The present research focused on studying the intangible value in the fuel sector in Peru as the main source of energy for various economic activities such as transportation service, power generation, industrial processes, among others; in addition, participates as an input in productive processes. However, in spite of its importance for the country, there are no studies that allow to know the impact of its impact on society. Therefore, the objective of the present study was to obtain the degree of implementation of intangible value in the four wholesale fuel distribution companies that have the highest percentage of participation in the peruvian market. To this end, surveys were carried out to obtain such information according to the percentage of c...
Cancers, 2021
Daratumumab is active both as a single agent and in combination with other agents in multiple mye... more Daratumumab is active both as a single agent and in combination with other agents in multiple myeloma (MM) patients. However, the majority of patients will develop daratumumab-refractory disease, which carries a poor prognosis. Since daratumumab also has immunomodulatory effects, addition of the PD-L1 blocking antibody durvalumab at the time of progression may reverse daratumumab-resistance. The efficacy and safety of daratumumab and durvalumab in daratumumab-refractory relapsed/refractory MM patients was evaluated in this prospective, single-arm phase 2 study (NCT03000452). None of the 18 enrolled patients achieved PR or better. The frequency of serious adverse events was 38.9%, with one patient experiencing an immune related adverse event (grade 2 hyperthyroidism). No infusion-related reactions were observed. Analysis of tumor- and immune cell characteristics was performed on bone marrow samples obtained at baseline and during treatment. Daratumumab combined with durvalumab reduce...
Clinical Cancer Research, 2020
Purpose: Multiple myeloma (MM) patients with disease refractory to all available drugs have a poo... more Purpose: Multiple myeloma (MM) patients with disease refractory to all available drugs have a poor outcome, indicating the need for new agents with novel mechanisms of action. Experimental Design: We evaluated the anti-MM activity of the fully human BCMA×CD3 bispecific antibody JNJ-7957 in cell lines and bone marrow (BM) samples. The impact of several tumor- and host-related factors on sensitivity to JNJ-7957 therapy was also evaluated. Results: We show that JNJ-7957 has potent activity against 4 MM cell lines, against tumor cells in 48 of 49 BM samples obtained from MM patients, and in 5 of 6 BM samples obtained from primary plasma cell leukemia patients. JNJ-7957 activity was significantly enhanced in patients with prior daratumumab treatment, which was partially due to enhanced killing capacity of daratumumab-exposed effector cells. BCMA expression did not affect activity of JNJ-7957. High T-cell frequencies and high effector:target ratios were associated with improved JNJ-7957–m...
Expert Review of Clinical Immunology, 2018
Introduction: Multiple myeloma (MM) is generally an incurable hematological malignancy with heter... more Introduction: Multiple myeloma (MM) is generally an incurable hematological malignancy with heterogeneous overall survival rates ranging from a few months to more than 10 years. Survival is especially poor for patients who developed disease that is refractory to immunomodulatory drugs and proteasome inhibitors. Areas covered: This review will discuss the importance of CD38-targeting antibodies for the treatment of MM patients to improve their outcome. Expert commentary: Intense immuno-oncological laboratory research has resulted in the development of functionally active monoclonal antibodies against cell surface markers present on MM cells. In this respect, CD38-targeting antibodies such as daratumumab, MOR202, and isatuximab, have high single agent activity in heavily pretreated MM patients by virtue of their pleiotropic mechanisms of action including Fc-dependent effector mechanisms and immunomodulatory activities. Importantly, CD38-targeting antibodies are well tolerated, with infusion reactions as most frequent adverse event. Altogether, this makes them attractive combination partners with other anti-MM agents. Daratumumab is already approved as monotherapy and in combination with lenalidomide-dexamethasone as well as bortezomibdexamethasone in pretreated MM patients. Furthermore, results from studies evaluating CD38targeting antibodies in newly diagnosed MM patients are also promising, indicating that CD38targeting antibodies will be broadly used in MM, resulting in further improvements in survival.
Supplemental Methods; Supplemental Figure legends; Supplemental Table 1; Figure S1, S2, S3, S4, S... more Supplemental Methods; Supplemental Figure legends; Supplemental Table 1; Figure S1, S2, S3, S4, S5, S6, S7, S8 and S9
The principle of intangible value in the world has acquired relevance as a corporate and social s... more The principle of intangible value in the world has acquired relevance as a corporate and social strategy, while in Peru it has been disseminated only at the academic level and its implementation in the various sectors has been very poor. The present research focused on studying the intangible value in the fuel sector in Peru as the main source of energy for various economic activities such as transportation service, power generation, industrial processes, among others; in addition, participates as an input in productive processes. However, in spite of its importance for the country, there are no studies that allow to know the impact of its impact on society. Therefore, the objective of the present study was to obtain the degree of implementation of intangible value in the four wholesale fuel distribution companies that have the highest percentage of participation in the peruvian market. To this end, surveys were carried out to obtain such information according to the percentage of c...
Cancers, 2021
Daratumumab is active both as a single agent and in combination with other agents in multiple mye... more Daratumumab is active both as a single agent and in combination with other agents in multiple myeloma (MM) patients. However, the majority of patients will develop daratumumab-refractory disease, which carries a poor prognosis. Since daratumumab also has immunomodulatory effects, addition of the PD-L1 blocking antibody durvalumab at the time of progression may reverse daratumumab-resistance. The efficacy and safety of daratumumab and durvalumab in daratumumab-refractory relapsed/refractory MM patients was evaluated in this prospective, single-arm phase 2 study (NCT03000452). None of the 18 enrolled patients achieved PR or better. The frequency of serious adverse events was 38.9%, with one patient experiencing an immune related adverse event (grade 2 hyperthyroidism). No infusion-related reactions were observed. Analysis of tumor- and immune cell characteristics was performed on bone marrow samples obtained at baseline and during treatment. Daratumumab combined with durvalumab reduce...
Clinical Cancer Research, 2020
Purpose: Multiple myeloma (MM) patients with disease refractory to all available drugs have a poo... more Purpose: Multiple myeloma (MM) patients with disease refractory to all available drugs have a poor outcome, indicating the need for new agents with novel mechanisms of action. Experimental Design: We evaluated the anti-MM activity of the fully human BCMA×CD3 bispecific antibody JNJ-7957 in cell lines and bone marrow (BM) samples. The impact of several tumor- and host-related factors on sensitivity to JNJ-7957 therapy was also evaluated. Results: We show that JNJ-7957 has potent activity against 4 MM cell lines, against tumor cells in 48 of 49 BM samples obtained from MM patients, and in 5 of 6 BM samples obtained from primary plasma cell leukemia patients. JNJ-7957 activity was significantly enhanced in patients with prior daratumumab treatment, which was partially due to enhanced killing capacity of daratumumab-exposed effector cells. BCMA expression did not affect activity of JNJ-7957. High T-cell frequencies and high effector:target ratios were associated with improved JNJ-7957–m...
Expert Review of Clinical Immunology, 2018
Introduction: Multiple myeloma (MM) is generally an incurable hematological malignancy with heter... more Introduction: Multiple myeloma (MM) is generally an incurable hematological malignancy with heterogeneous overall survival rates ranging from a few months to more than 10 years. Survival is especially poor for patients who developed disease that is refractory to immunomodulatory drugs and proteasome inhibitors. Areas covered: This review will discuss the importance of CD38-targeting antibodies for the treatment of MM patients to improve their outcome. Expert commentary: Intense immuno-oncological laboratory research has resulted in the development of functionally active monoclonal antibodies against cell surface markers present on MM cells. In this respect, CD38-targeting antibodies such as daratumumab, MOR202, and isatuximab, have high single agent activity in heavily pretreated MM patients by virtue of their pleiotropic mechanisms of action including Fc-dependent effector mechanisms and immunomodulatory activities. Importantly, CD38-targeting antibodies are well tolerated, with infusion reactions as most frequent adverse event. Altogether, this makes them attractive combination partners with other anti-MM agents. Daratumumab is already approved as monotherapy and in combination with lenalidomide-dexamethasone as well as bortezomibdexamethasone in pretreated MM patients. Furthermore, results from studies evaluating CD38targeting antibodies in newly diagnosed MM patients are also promising, indicating that CD38targeting antibodies will be broadly used in MM, resulting in further improvements in survival.